"Stable for two years at −20 °C" is the kind of sentence that appears on technical sheets and storage guides. Behind a statement like that, in pharmaceutical development at least, sits a formal study design with defined temperatures, humidities, time points and test methods. Knowing how those studies are built makes it easier to judge any stability claim you read, including claims about research peptides.
The international reference is the International Council for Harmonisation (ICH) guideline Q1A(R2), Stability Testing of New Drug Substances and Products, with Q1B covering photostability. ICH guidelines are written for registered medicines. Research materials are not held to them, but they are the clearest model of what good stability evidence looks like.
What a Stability Study Is For
ICH Q1A(R2) states that the purpose of stability testing is to provide evidence on how the quality of a substance varies with time under the influence of environmental factors such as temperature, humidity and light. The output is a recommended storage condition and a period during which the material is expected to stay within its specification.
For a drug substance, Q1A calls that period the re-test period: the time during which the substance is expected to remain within specification when stored under defined conditions. After it, the material should be re-tested before use rather than assumed to be unchanged.
Scope: Where Peptides Fit
Q1A(R2) covers new chemical drug substances and products. Biotechnological and biological products have their own ICH guideline, Q5C. Short synthetic peptides are made chemically, so the chemical-stability framework of Q1A is the closer model for them, although peptide chemistry has degradation pathways that small molecules do not. Our guide on Peptide-Related Impurities describes those pathways, such as oxidation, deamidation and aggregation.
Step One: Stress Testing
Before formal studies begin, Q1A(R2) describes stress testing of the substance. Its purposes are to:
- identify likely degradation products,
- establish degradation pathways and the molecule's intrinsic stability, and
- show that the analytical method is stability-indicating, meaning it can actually detect those degradation products.
Q1A(R2) says stress testing is likely to be done on a single batch and should include:
- Temperature in 10 °C steps above the accelerated condition (for example 50 °C, 60 °C).
- Humidity of 75% relative humidity or more, where appropriate.
- Oxidation.
- Photolysis (light).
- Hydrolysis across a wide range of pH when the substance is in solution or suspension.
Stress testing is deliberately harsh. Its job is not to predict storage life but to find out what can go wrong and make sure the method can see it. The link between this step and method validation is covered in Is the Test Method Fit for Purpose?
Step Two: Formal Studies on Representative Batches
Q1A(R2) asks for formal stability data on at least three primary batches, made at minimum pilot scale by the same synthetic route and a process that simulates the final one. One batch can behave unusually. Three give some sense of batch-to-batch consistency.
The material should be stored in a container closure system that is the same as, or simulates, the packaging used for storage and distribution. Stability data for powder in a sealed glass vial under inert gas say little about the same powder in an unsealed tube.
The Standard Storage Conditions
Q1A(R2) defines condition sets by intended storage. The table below summarises the main ones for drug substances.
| Intended storage | Study | Condition | Minimum data period at submission |
|---|---|---|---|
| General case | Long-term | 25 °C ± 2 °C / 60% RH ± 5% (or 30 °C / 65% RH) | 12 months |
| General case | Intermediate | 30 °C ± 2 °C / 65% RH ± 5% | 6 months |
| General case | Accelerated | 40 °C ± 2 °C / 75% RH ± 5% | 6 months |
| Refrigerator | Long-term | 5 °C ± 3 °C | 12 months |
| Refrigerator | Accelerated | 25 °C ± 2 °C / 60% RH ± 5% | 6 months |
| Freezer | Long-term | −20 °C ± 5 °C | 12 months |
For freezer storage, which is common for lyophilized peptides, Q1A(R2) notes there is no standard accelerated condition. The re-test period should be based on real-time data at the long-term condition. It recommends testing a single batch at an elevated temperature (for example 5 °C or 25 °C) for an appropriate period to address the effect of short excursions, such as during shipping or handling.
That point is worth remembering. A credible "stable at −20 °C" claim rests on real-time data at −20 °C, not on an extrapolation from a few weeks at room temperature.
Time Points
For long-term studies, Q1A(R2) describes testing every 3 months over the first year, every 6 months over the second year, and annually after that through the proposed re-test period. At the accelerated condition, a minimum of three time points including the start and end, for example 0, 3 and 6 months.
Each time point is a full set of tests against the specification, usually including appearance, purity by a stability-indicating method, and impurities.
What Counts as "Significant Change"
For a drug substance, Q1A(R2) defines significant change simply as failure to meet its specification. If significant change occurs at the accelerated condition, intermediate testing or a more cautious, real-time-based re-test period follows.
That definition depends entirely on the specification. A material with a loose impurity limit can "pass" while degrading noticeably. When you read a stability claim, ask what the acceptance criteria were.
Photostability: ICH Q1B
Light can drive oxidation, especially of tryptophan, tyrosine and methionine residues. ICH Q1B describes two kinds of light study.
- Forced degradation studies evaluate overall photosensitivity, for method development and to understand degradation pathways.
- Confirmatory studies expose samples to an overall illumination of not less than 1.2 million lux hours and integrated near-ultraviolet energy of not less than 200 watt-hours per square metre.
If a material degrades under confirmatory exposure, the next step is to test it in protective packaging such as amber glass or an outer carton. This is the formal basis for "protect from light" on a label. Practical storage advice is in Storing Lyophilized Peptides.
Why Lyophilized Powder Is Usually More Stable
Removing water slows hydrolysis and many other reactions. That is the main reason peptides are supplied as freeze-dried powder, as explained in Why Peptides Ship as a Dry Powder. It does not stop every reaction. For example, a study of peptides derived from human growth hormone found that thiol-disulfide exchange can still occur during lyophilization and in the dried solid during storage. "Dry" means slower, not frozen in time.
Reading a Stability Claim Critically
When a document says a material is stable under some condition, ask:
- What condition, exactly? Temperature, humidity, light protection and packaging.
- For how long, and was it real-time data or extrapolated from accelerated conditions?
- How many batches were studied?
- Which method measured it, and was that method shown to be stability-indicating?
- What was the acceptance criterion? "Within specification" means different things for different specifications.
- Does it apply to the form you have? Data on powder do not apply to a solution, and data on one salt form may not apply to another.
A stability claim without these details is a description of an expectation, not evidence.
FAQ
Is "accelerated stability" a way to predict shelf life quickly? It provides supporting data and can flag problems early. Q1A(R2) still bases the re-test period on long-term data, and for freezer-stored substances specifically on real-time data at the long-term condition.
Why three batches? One batch can be unusually good or bad. Three give a minimal picture of consistency between batches.
Does a short time at room temperature ruin a lyophilized peptide? Not necessarily. That is what excursion data address. The answer depends on the specific compound, packaging and duration, which is why single-batch excursion testing exists.
Sources
- International Council for Harmonisation. ICH Q1A(R2) Stability Testing of New Drug Substances and Products, 2003: https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf
- International Council for Harmonisation. ICH Q1B Photostability Testing of New Drug Substances and Products, 1996: https://database.ich.org/sites/default/files/Q1B%20Guideline.pdf
- Chandrasekhar S, Topp EM. Thiol-disulfide exchange in peptides derived from human growth hormone during lyophilization and storage in the solid state. Journal of Pharmaceutical Sciences, 2015. PMC4359671: https://pmc.ncbi.nlm.nih.gov/articles/PMC4359671/
Every Peptide Privé batch is tested by an independent lab.
Contact our team with documentation questions.
For in-vitro laboratory research only. Not for human or animal use.
